Related references
Note: Only part of the references are listed.Quality of Life Improvement in Patients Treated with Degarelix versus Leuprorelin for Advanced Prostate Cancer
Dawn Lee et al.
JOURNAL OF UROLOGY (2015)
Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Peter C. Albertsen et al.
EUROPEAN UROLOGY (2014)
Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists
Laurence Klotz et al.
EUROPEAN UROLOGY (2014)
Degarelix versus Goserelin plus Bicalutamide Therapy for Lower Urinary Tract Symptom Relief, Prostate Volume Reduction and Quality of Life Improvement in Men with Prostate Cancer: A Systematic Review and Meta-Analysis
Yuanshan Cui et al.
UROLOGIA INTERNATIONALIS (2014)
Prospective Evaluation of Testosterone Fluctuations During a Transition of Therapy From Degarelix to Leuprolide in Patients on Androgen Deprivation Therapy
Jack M. Zuckerman et al.
UROLOGY (2014)
Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix
E. David Crawford et al.
UROLOGY (2014)
A cost–utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom
Dawn Lee et al.
JOURNAL OF MEDICAL ECONOMICS (2014)
Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide
M. Mason et al.
CLINICAL ONCOLOGY (2013)
ANDROGEN DEPRIVATION THERAPY BY A GONADOTROPIN RELEASING HORMONE ANTAGONIST, DEGARELIX, LOWERS THE RISK OF CARDIOVASCULAR EVENTS OR DEATH WHEN COMPARED TO LUTEINISING HORMONE-RELEASING AGONISTS
Peter Albertsen et al.
JOURNAL OF UROLOGY (2013)
DEGARELIX INDUCTION FOLLOWED BY LEUPROLIDE MAINTENANCE: A NEW TREATMENT PARADIGM?
Jack Zuckerman et al.
JOURNAL OF UROLOGY (2013)
ANALYSIS OF DISEASE CONTROL-RELATED OUTCOMES FROM SIX COMPARATIVE RANDOMISED CLINICAL TRIALS OF DEGARELIX VERSUS LUTEINISING HORMONE-RELEASING HORMONE AGONISTS
Neal Shore et al.
JOURNAL OF UROLOGY (2013)
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
N. D. Shore et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2013)
Degarelix versus Goserelin ( plus Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)
John Anderson et al.
UROLOGIA INTERNATIONALIS (2013)
Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer
Hind T. Hatoum et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2013)
New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist
Marc B. Garnick et al.
BJU INTERNATIONAL (2012)
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide
Karol Axcrona et al.
BJU INTERNATIONAL (2012)
985 ADT for volume reduction, symptom relief and quality of life improvement in men with prostate cancer: Degarelix versus goserelin plus bicalutamide
K. Axcrona et al.
EUROPEAN UROLOGY SUPPLEMENTS (2012)
PROSTATE CANCER Making the switch from LHRH antagonist to LHRH agonist
Judd W. Moul
NATURE REVIEWS UROLOGY (2012)
The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From A 12-Month, Comparative, Phase III Study in Prostate Cancer Patients
Jan-Erik Damber et al.
UROLOGY (2012)
Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer
J. de la Rosette et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Gonadotropin-Releasing Hormone Blockers and Cardiovascular Disease Risk: Analysis of Prospective Clinical Trials of Degarelix
Matthew R. Smith et al.
JOURNAL OF UROLOGY (2011)
A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer
E. David Crawford et al.
JOURNAL OF UROLOGY (2011)
Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide
P. Iversen et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2011)
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
Fritz H. Schroder et al.
BJU INTERNATIONAL (2010)
Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
Bertrand Tombal et al.
EUROPEAN UROLOGY (2010)
CARDIOVASCULAR SAFETY OF DEGARELIX: RESULTS FROM A 12-MONTH, COMPARATIVE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III TRIAL IN PROSTATE CANCER PATIENTS
Laurence Klotz et al.
JOURNAL OF UROLOGY (2010)
PROSTATE-SPECIFIC ANTIGEN AND SERUM ALKALINE PHOSPHATASE LEVELS IN PROSTATE CANCER PATIENTS RECEIVING DEGARELIX OR LEUPROLIDE
E. David Crawford et al.
JOURNAL OF UROLOGY (2010)
Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer
Matthew R. Smith et al.
JOURNAL OF UROLOGY (2010)
Degarelix versus leuprolide in patients with metastatic prostate cancer: assessment of serum alkaline phosphatase over time
F. Schroeder et al.
EJC SUPPLEMENTS (2009)
Degarelix versus leuprolide in prostate cancer patients: new prostate-specific antigen data from a phase III trial (CS21)
B. Tombal et al.
EJC SUPPLEMENTS (2009)
COMPARING TESTOSTERONE AND PSA FOR DIFFERENT BASELINE TESTOSTERONE CONCENTRATIONS DURING INITIATION OF DEGARELIX AND LEUPROLIDE TREATMENT
J. E. Damber et al.
EUROPEAN UROLOGY SUPPLEMENTS (2009)
DEGARELIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: EFFECT IN METASTATIC PATIENTS AS ASSESSED BY SERUM ALKALINE PHOSPHATASE
F. H. Schroder et al.
EUROPEAN UROLOGY SUPPLEMENTS (2009)
DEGARELIX VS. LEUPROLIDE TREATMENT IN PATIENTS WITH ADVANCED PROSTATE CANCER: PSA FAILURES DURING A RANDOMISED, PHASE III TRIAL (CS21)
B. Tombal et al.
EUROPEAN UROLOGY SUPPLEMENTS (2009)
Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31
Jason A. Efstathiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
PLOS MEDICINE (2009)
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz et al.
BJU INTERNATIONAL (2008)
Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02
Jason A. Efstathiou et al.
EUROPEAN UROLOGY (2008)
Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group phase III study in prostate cancer patients
L. Boccon-Gibod et al.
EUROPEAN UROLOGY SUPPLEMENTS (2008)
An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists
M Koch et al.
UROLOGY (2003)
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer
D McLeod et al.
UROLOGY (2001)
The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
K Tomera et al.
JOURNAL OF UROLOGY (2001)
Share Paper
